BIOA (Bioage Labs) Total Tax Payable : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bioage Labs Total Tax Payable?

Bioage Labs's Total Tax Payable for the quarter that ended in Dec. 2024 was $0.00 Mil.

Bioage Labs Total Tax Payable Historical Data

The historical data trend for Bioage Labs's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioage Labs Total Tax Payable Chart

Bioage Labs Annual Data

Trend

Dec22

Dec23

Dec24

Total Tax Payable

Bioage Labs Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Tax Payable	Get a 7-Day Free Trial				-	-	-	-	-

Bioage Labs Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Bioage Labs Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Bioage Labs's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioage Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bioage Labs Inc (NAS:BIOA) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

Y7G:Germany

Address

1445A South 50th Street, Richmond, CA, USA, 94804

Website

https://www.bioagelabs.com

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.